1Chen LX, Schumacher HR. Goul: an evidence -based review [J]. Clin Rheumaiol, 2008, 14 (Suppl 5): S55- 62.
2Halevy S, Ghislain P, Mockenhaupt M, et al. Allopuri-nol is the most common cause of Stevens-Johnson syn-drome and toxic epidermal necrolysis in Europe and Israel!:J]. Am. Acad Dermatol, 2008, 58(1): 25-32.
3Tausche AK, Aringer M, Schroeder HE, el al. The Janus faces of allopurinol -allopurinol hypersensitivity syndrome[J]. A In J Med, 2008, 121 (3): e3-4.
4Kim SC, Newcomb C, Margolis D, et al. Severe Cuta-neous Reactions requiring Hospitalization in Allopurinol Initiators: a Population-based Cohort Study [J]. Arthritis Care Res, 2012, 16(10): 1002.
5Wong GA, Shear N.H. Is a drug alone sufficient to cause the drug hypersensitivity syndrome [J]. A rch. Deroo malol; 2004, 140(2): 226-30.
4Farquhanson CA, Bufer R, Hill A, et al. Allopufinol improves endotheli-al dysfunction in chronic heart failure [ J ]. Circulation, 2002, 106 (2) :221-226.
5Hamoka H, Mazatani H, Nouchi N, et al. Allopurinol hypersensitivity syndrome hypersensitivity to oxypurinol but not allopurinol [ J ]. Clin EXP Dennatol, 1998,23 ( 1 ) :32-34.
6Sullivan JR, Shear NH. The drug hypersensitivity sydrome: What is thepathogenesis. [ J ]. Arch Dermatol,2001,137 ( 3 ) : 357-364.
